stoxline Quote Chart Rank Option Currency Glossary
  
Protara Therapeutics, Inc. (TARA)
4.15  0.05 (1.22%)    02-12 16:09
Open: 4.08
High: 4.195
Volume: 356,378
  
Pre. Close: 4.1
Low: 3.92
Market Cap: 142(M)
Technical analysis
2025-02-12 4:48:23 PM
Short term     
Mid term     
Targets 6-month :  6.1 1-year :  7.05
Resists First :  5.23 Second :  6.03
Pivot price 4.57
Supports First :  3.92 Second :  3.26
MAs MA(5) :  4.26 MA(20) :  4.59
MA(100) :  3.61 MA(250) :  3.14
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  7.3 D(3) :  6.8
RSI RSI(14): 37
52-week High :  10.47 Low :  1.59
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ TARA ] has closed above bottom band by 15.0%. Bollinger Bands are 22.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.2 - 4.22 4.22 - 4.25
Low: 3.86 - 3.89 3.89 - 3.92
Close: 4.11 - 4.15 4.15 - 4.19
Company Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Headline News

Sat, 08 Feb 2025
Certain Common Warrants of Protara Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com

Wed, 05 Feb 2025
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire

Wed, 05 Feb 2025
Exclusive Healthcare Insights: Protara Therapeutics Takes Center Stage at Major Oppenheimer Conference - StockTitan

Wed, 05 Feb 2025
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Significant Drop in Short Interest - MarketBeat

Sat, 14 Dec 2024
Protara Therapeutics: Rising From The Ashes (NASDAQ:TARA) - Seeking Alpha

Tue, 10 Dec 2024
Protara Therapeutics: Carving New Roads In Bladder Cancer (TARA) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 35 (M)
Shares Float 15 (M)
Held by Insiders 6.1 (%)
Held by Institutions 51.1 (%)
Shares Short 2,740 (K)
Shares Short P.Month 2,150 (K)
Stock Financials
EPS -2.65
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.01
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -28.2 %
Return on Equity (ttm) -46 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.27
Qtrly Earnings Growth 0 %
Operating Cash Flow -33 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio -1.58
PEG Ratio 0
Price to Book value 0.69
Price to Sales 0
Price to Cash Flow -4.33
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android